Matthew C. Abernethy
2017
In 2017, Matthew C. Abernethy earned a total compensation of $3.8M as Chief Financial Officer at Neurocrine Biosciences.
Compensation breakdown
| Bonus | $20,071 |
|---|---|
| Option Awards | $2,416,800 |
| Salary | $38,231 |
| Stock Awards | $920,000 |
| Other | $394,190 |
| Total | $3,789,292 |
Abernethy received $2.4M in option awards, accounting for 64% of the total pay in 2017.
Abernethy also received $20.1K in bonus, $38.2K in salary, $920K in stock awards and $394.2K in other compensation.
Rankings
In 2017, Matthew C. Abernethy's compensation ranked 2,745th out of 14,666 executives tracked by ExecPay. In other words, Abernethy earned more than 81.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,745 out of 14,666 | 81st |
Division Manufacturing | 950 out of 5,770 | 84th |
Major group Chemicals And Allied Products | 252 out of 2,074 | 88th |
Industry group Drugs | 191 out of 1,730 | 89th |
Industry Biological Products, Except Diagnostic Substances | 35 out of 316 | 89th |
Source: SEC filing on April 17, 2019.
Abernethy's colleagues
We found four more compensation records of executives who worked with Matthew C. Abernethy at Neurocrine Biosciences in 2017.
News
Neurocrine Biosciences CEO Kevin Gorman's 2021 pay rises 1% to $14M
April 7, 2022
Neurocrine Biosciences CEO Kevin Gorman's 2020 pay jumps 47% to $14M
April 9, 2021
Neurocrine Biosciences CEO Kevin Gorman's 2019 pay rises 9% to $9.5M
April 9, 2020
Neurocrine Biosciences CEO Kevin Gorman's 2018 pay rises 14% to $8.6M
April 17, 2019